I. REPORT ON BUSINESS AND PRODUCTION RESULTS IN JAN 2022
Total net revenue and other income of Imexpharm in Jan 2022 reached VND 97.4 billion, which decreased by 17.2% year over year. While the Company recorded net revenue of VND 96.3 billion, reducing by 18.1% compared to the same period of the previous year. Although the pandemic has appeared to be winding down in the South of Vietnam, the market has not yet fully recovered. Hence, the revenue of Imexpharm in Jan 2022 plummeted in comparison with the previous year. In Jan 2022, Imexpharm sold products manufactured by the Company and did not have franchised products or export products in revenue structure. OTC and ETC revenue all fell by 18.9% and 17.4% respectively compared to the figure of Jan 2021.
(Unit: Billion dongs)
| Criteria |
Jan 2022 |
Jan 2021 |
Growth rate |
| Total net revenue and other income |
97.4 |
117.7 |
(17.2)% |
| Net revenue |
96.3 |
117.6 |
(18.1)% |
| Profit before tax |
19.1 |
20.1 |
(5.0)% |
However, the Company has been well-controlling expenses whilst the cost of goods sold declined by 24.3% year over year. Simultaneously, selling and administrative expenses also dropped by 9.9% and 15.1% respectively. Despite pushing activities to stimulate demand after the pandemic is under control, Imexpharm has been implementing prudently to meet the requirements of preventing and fighting against the pandemic as well as monitor expenditures effectively to maintain the level of profit margin. Thus, in spite of a sharp decrease in revenue, profit before tax of the Company went down only 5%.
II. IMPSTOCK IN JANUARY 2021
Total transactions volume of IMP stock in Jan 2022 were 268,100 shares in which 141,000 stocks were traded via order matching and 127,100 were dealt by the put-through method. The total amount of transaction shares in Jan 2022 was only 19.5% of the number of Jan 2021. While the number of shares traded via put through method was approximately the figure of the corresponding period last year, the amount of order marched stocks was only 11.4% of the previous year’s volume. IMP stock in Jan 2022 experienced lower liquidity than the same period last year while the stock price surged and shareholder structure has changed in comparison with the beginning of 2021.
III. REMARKABLE ACTIVITIES IN JAN 2022 AND PLANS FOR FEB 2022
In Jan 2022, Imexpharm has collected shareholders’ opinions in writing and disclosed the relevant Resolution on Jan 28, 2022. In which, the General Meeting of Shareholders has approved to increase the maximum foreign ownership at Imexpharm to 75% and accepted to waive public tender offering for SK Investment Vina III at Imexpharm to raise its ownership to over 45%.
Additionally, in Jan 2022 Imexpharm has conducted a closing ceremony for 2021 and proposed overall and detailed strategies for 2022 with the motto “ safety for all employees first and maintain business and production continuity and effectiveness”.
In 2022, Imexpharm employees shall be back to work after a long holiday, the Company has conducted procedures following the guidelines of the Ministry of Health and other authorities to protect all staff and ensure business continuity of Imexpharm.
Imexpharm’s meeting of the General Meeting of Shareholders would be tentatively organized in April 2022; therefore, the Company will prepare for it in Feb and Mar to conduct a successful meeting.
In addition, the Company is following closely the schedule to accredit EU-GMP for IMP4 when the travel restrictions are being eased in Europe. Imepxharm hopes that IMP4 would be certified EU-GMP in quarter 1 or quarter 2 of 2022.